Deal Watch: Fresenius Drops Bid For Akorn, Citing Data-Integrity Concerns
Executive Summary
Janssen and Bristol team to develop next-generation oral anticoagulant, while UCB buys Proximagen's nasal spray candidate and Duke spinout focused on genomics.
You may also be interested in...
BMS/Celgene Post-Merger Early R&D Strategy: Partnerships Are Still Key, Vessey Says
Research and early development head Rupert Vessey, who had a similar role at Celgene, told Scrip that integration of the company’s pipeline into Bristol is nearly complete with few overlapping programs.
Basilea Says Phase II Derazantinib Data Keep Drug’s Prospects On Track
Basilea reported positive interim results from its registrational Phase II study with oncology drug candidate derazantinib in intrahepatic cholangiocarcinoma, or bile duct cancer.
Amid PD-1 Uncertainty, Bristol Under Pressure For M&A Activity
Bristol says its checkpoint immunotherapies can hold the lead in renal cell carcinoma, despite increasing competition.